2430 related articles for article (PubMed ID: 26630143)
1. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA; Claggett B; Diaz R; Dickstein K; Gerstein HC; Køber LV; Lawson FC; Ping L; Wei X; Lewis EF; Maggioni AP; McMurray JJ; Probstfield JL; Riddle MC; Solomon SD; Tardif JC;
N Engl J Med; 2015 Dec; 373(23):2247-57. PubMed ID: 26630143
[TBL] [Abstract][Full Text] [Related]
2. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
Muskiet MHA; Tonneijck L; Huang Y; Liu M; Saremi A; Heerspink HJL; van Raalte DH
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):859-869. PubMed ID: 30292589
[TBL] [Abstract][Full Text] [Related]
3. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
[TBL] [Abstract][Full Text] [Related]
4. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
Bentley-Lewis R; Aguilar D; Riddle MC; Claggett B; Diaz R; Dickstein K; Gerstein HC; Johnston P; Køber LV; Lawson F; Lewis EF; Maggioni AP; McMurray JJ; Ping L; Probstfield JL; Solomon SD; Tardif JC; Wu Y; Pfeffer MA;
Am Heart J; 2015 May; 169(5):631-638.e7. PubMed ID: 25965710
[TBL] [Abstract][Full Text] [Related]
5. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
6. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Husain M; Birkenfeld AL; Donsmark M; Dungan K; Eliaschewitz FG; Franco DR; Jeppesen OK; Lingvay I; Mosenzon O; Pedersen SD; Tack CJ; Thomsen M; Vilsbøll T; Warren ML; Bain SC;
N Engl J Med; 2019 Aug; 381(9):841-851. PubMed ID: 31185157
[TBL] [Abstract][Full Text] [Related]
7. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR; Bethel MA; Mentz RJ; Thompson VP; Lokhnygina Y; Buse JB; Chan JC; Choi J; Gustavson SM; Iqbal N; Maggioni AP; Marso SP; Öhman P; Pagidipati NJ; Poulter N; Ramachandran A; Zinman B; Hernandez AF;
N Engl J Med; 2017 Sep; 377(13):1228-1239. PubMed ID: 28910237
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ;
N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427
[TBL] [Abstract][Full Text] [Related]
9. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Derosa G; Maffioli P
N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.
Wijkman MO; Claggett B; Diaz R; Gerstein HC; Køber L; Lewis E; Maggioni AP; Wolsk E; Aguilar D; Bentley-Lewis R; McMurray JJ; Probstfield J; Riddle M; Tardif JC; Solomon SD; Pfeffer MA
Cardiovasc Diabetol; 2020 Oct; 19(1):175. PubMed ID: 33046070
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Gerstein HC; Sattar N; Rosenstock J; Ramasundarahettige C; Pratley R; Lopes RD; Lam CSP; Khurmi NS; Heenan L; Del Prato S; Dyal L; Branch K;
N Engl J Med; 2021 Sep; 385(10):896-907. PubMed ID: 34215025
[TBL] [Abstract][Full Text] [Related]
13. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
[TBL] [Abstract][Full Text] [Related]
14. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
[TBL] [Abstract][Full Text] [Related]
15. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
[TBL] [Abstract][Full Text] [Related]
16. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB; Bethel MA; Armstrong PW; Buse JB; Engel SS; Garg J; Josse R; Kaufman KD; Koglin J; Korn S; Lachin JM; McGuire DK; Pencina MJ; Standl E; Stein PP; Suryawanshi S; Van de Werf F; Peterson ED; Holman RR;
N Engl J Med; 2015 Jul; 373(3):232-42. PubMed ID: 26052984
[TBL] [Abstract][Full Text] [Related]
17. Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.
Seferovic JP; Bentley-Lewis R; Claggett B; Diaz R; Gerstein HC; Køber LV; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Pfeffer MA
J Diabetes Res; 2018; 2018():1631263. PubMed ID: 30648112
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]